<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01085526</url>
  </required_header>
  <id_info>
    <org_study_id>BasoScit</org_study_id>
    <nct_id>NCT01085526</nct_id>
  </id_info>
  <brief_title>Changes in Specific Immunoglobulin and Blood Basophil Activity During Subcutaneous Immunotherapy in Allergic Rhinitis</brief_title>
  <official_title>Changes in Specific Immunoglobulin and Blood Basophil Activity During Subcutaneous Immunotherapy in Patients With Allergic Rhinitis Due to Grass Pollen Allergy - a Prospective Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ALK-Abelló A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lundbeck Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is randomized prospective study to examine the effects of subcutaneous
      immunotherapy on the adaptive immune system. The trial includes 30 participants randomized to
      treatment or control group. The effect measures are changes in the basophil activity and
      biology as well as changes in plasma cells during and after treatment. Clinical outcome is
      assessed by QoL questionnaires and clinical testing.

      Hypotheses:

        -  changes in plasma cells correlate to changes in immunoglobulins and effector cell
           responses

        -  the reduction of inflammation due to SCIT has influence on the effector cell responses

        -  changes in paraclinical measurements can be related to clinical findings
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are recruiting 30 participants, which are randomized to receive SCIT (24)
      or no treatment (6) The following will be measured

        -  the development of immunoglobulin response

        -  plasma cells under updosing phase

        -  changes in basophil activity under updosing and maintenance treatment

        -  subtyping of allergic sensitization

        -  clinical outcome and quality of life

        -  changes in mast cells in the nasal mucosa

        -  changes in the cell biology of the basophils
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>a significant decrease in basophil activity during and after treatment</measure>
    <time_frame>every 3 weeks for 3 months, then 3 monthly for 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>reduction in high affinity IgE receptor density on basophils and mast cells</measure>
    <time_frame>at inclusion and at the end of study</time_frame>
    <description>igE receptor density on basophils and mast cells from nasal mucosa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical outcome: reduction in the reaction to allergen challenge tests (skin and nose), significant better outcome in quality of life questionnaires and symptom/medication scores</measure>
    <time_frame>once yearly for 4 years</time_frame>
    <description>allergen challenging response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a significant increase in the number of plasma cells during up dosing</measure>
    <time_frame>5 times during the first 3 months of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a significant shift in specific immunoglobulins from IgE at start to IgG1 and IgG4 after treatment. allergen epitope specific IgE and IgG4</measure>
    <time_frame>every 3 months for 4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Allergic Rhinoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>alutard phl prat. treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>18 subjects receiving active treatment: basophil activity, plasma cells and immunoglobulins measured</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>alutard phl.prat., treatment group2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>basophil activity, basophil biology measured</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Alutard phleum pratense subcutaneous immunotherapy</intervention_name>
    <description>standard regimen of SCIT</description>
    <arm_group_label>alutard phl prat. treatment group</arm_group_label>
    <arm_group_label>alutard phl.prat., treatment group2</arm_group_label>
    <other_name>alutard phleum pratense</other_name>
    <other_name>subcutaneous immunotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alutard phl prat</intervention_name>
    <arm_group_label>alutard phl prat. treatment group</arm_group_label>
    <arm_group_label>alutard phl.prat., treatment group2</arm_group_label>
    <other_name>Alutard 225, phleum pratense, ALK-abelló</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  rhinoconjunctivitis due to grass pollen allergy

          -  positive skin prick test and nasal allergen challenge test to grass pollen extract

        Exclusion Criteria:

          -  severe comorbidity, severe asthma, pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Dahl, Prof, dr.med</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. of Respiratory Medicine, Århus University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hans Juergen Hoffmann, assoc prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Respiratory Medicine, Århus University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johannes M Schmid, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Respiratory Medicine, Aarhus University Hospital</affiliation>
  </overall_official>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2010</study_first_submitted>
  <study_first_submitted_qc>March 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2010</study_first_posted>
  <last_update_submitted>February 16, 2015</last_update_submitted>
  <last_update_submitted_qc>February 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Pia Pedersen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>basophil activity</keyword>
  <keyword>plasma cells</keyword>
  <keyword>IgE</keyword>
  <keyword>IgG1</keyword>
  <keyword>IgG4</keyword>
  <keyword>mast cells</keyword>
  <keyword>IgE receptor</keyword>
  <keyword>allergic rhinoconjunctivitis</keyword>
  <keyword>grass pollen allergy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

